Pancreatic Cancer Research

ResearcherVA Greater Los Angeles Healthcare SystemActive in the last 2 years

Mark D. Girgis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8085-4422; OpenAlex author ID A5045636811, A5109662627. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 14

  1. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  2. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Co-author DOI 10.1038/s41467-026-68976-2↗
  3. Inhibition of AXL dependent non-professional efferocytosis sensitizes pancreatic cancer to immune checkpoint blockade Last author DOI 10.1101/2025.08.12.669943↗
  4. Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resec… Last author DOI 10.1002/jso.27674↗
  5. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  6. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  7. 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2967/jnumed.121.261952↗
  8. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients. Last author DOI 10.1002/jso.26279↗
  9. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Co-author DOI 10.1016/j.surg.2019.12.008↗
  10. A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer. Co-author DOI 10.1007/s11605-017-3607-7↗
  11. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6290-8↗
  12. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Co-author DOI 10.1038/bjc.2016.121↗
  13. A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. First author DOI 10.1007/s11307-014-0733-4↗
  14. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. Co-author DOI 10.1016/j.jss.2013.05.095↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Timothy R. Donahue · 11 shared papers, 2016–2026 · strength 1.71
  2. Zev A. Wainberg · 8 shared papers, 2016–2026 · strength 1.11
  3. Joon Y. Park · 5 shared papers, 2021–2025 · strength 0.92
  4. Oscar Joe Hines · 6 shared papers, 2016–2026 · strength 0.80
  5. Jonathan C. King · 4 shared papers, 2021–2026 · strength 0.79
  6. Jason M. Link · 3 shared papers, 2024–2026 · strength 0.60
  7. Shimpei Maeda · 4 shared papers, 2020–2026 · strength 0.60
  8. Keith D. Lillemoe · 3 shared papers, 2022–2026 · strength 0.51
  9. Michael A. Mederos · 3 shared papers, 2021–2024 · strength 0.47
  10. Takayuki Shimizu · 2 shared papers, 2024–2026 · strength 0.39
  11. Motaz Qadan · 2 shared papers, 2022–2026 · strength 0.34
  12. Howard A. Reber · 4 shared papers, 2016–2021 · strength 0.34
  13. David W. Dawson · 2 shared papers, 2021–2026 · strength 0.34
  14. Carlos F. Fernandez-del Castillo · 2 shared papers, 2022–2024 · strength 0.28
  15. William R. Burns · 2 shared papers, 2022–2024 · strength 0.28
  16. Jun Yu · 2 shared papers, 2022–2024 · strength 0.28
  17. Cristina Rosa Ferrone · 2 shared papers, 2022–2024 · strength 0.28
  18. Hoang Dao · 1 shared paper, 2025 · strength 0.28
  19. Erina Vlashi · 1 shared paper, 2025 · strength 0.28
  20. Dustin L. Dillon · 1 shared paper, 2024 · strength 0.23
  21. William Reece Burns · 1 shared paper, 2026 · strength 0.23
  22. Theodore Sunki Hong · 1 shared paper, 2026 · strength 0.23
  23. Carlos Fernández-del Castillo · 1 shared paper, 2026 · strength 0.23
  24. Jin He · 1 shared paper, 2026 · strength 0.23
  25. Jennifer Yon-Li Wo · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.